Contributors: IRCCS Istituto Nazionale dei Tumori Milano; Yonsei University College of Medicine; CHA Bundang Medical Center; Service Pneumologie-Allergologie CHU Toulouse; Pôle Clinique des Voies respiratoires CHU Toulouse; Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse); Catholic University of Leuven = Katholieke Universiteit Leuven (KU Leuven); Chemistry, Oncogenesis, Stress and Signaling (COSS); Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC); UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM); Hospital Universitario Virgen del Rocío Sevilla; H. Lee Moffitt Cancer Center and Research Institute; Carolina BioOncology Institute; Service de Pneumologie CHI Créteil; CHI Créteil; IMRB - CEPIA/"Clinical Epidemiology And Ageing : Geriatrics, Primary Care and Public Health" Créteil (U955 Inserm - UPEC); Institut Mondor de Recherche Biomédicale (IMRB); Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12); Azienda Ospedaliera San Gerardo; The Ottawa Hospital Research Institute, Centre for Rehabilitation Research and Development, 505 Smyth Road, Ottawa, ON, Canada, K1H 8M2.; Samsung Medical Center Sungkyunkwan University School of Medicine; Institute Division of Hematology/Oncology; National University Hospital and National University Cancer Institute; AstraZeneca, Gaithersburg, MD, USA; AstraZeneca Cambridge, UK; Columbia University New York; Università degli studi di Torino = University of Turin (UNITO); Institut de Cancérologie de l'Ouest Angers/Nantes (UNICANCER/ICO); UNICANCER; Department of Mathematics Imperial College London; Imperial College London; Université libre de Bruxelles (ULB); Department of Microbiology; Chang Won National University; German Center for Lung Research; Università degli studi di Palermo - University of Palermo
نبذة مختصرة : International audience ; has a patent T-cell immunotherapy development pending; is a founder and owner of BioCytics, which is a clinical research laboratory developing T-cell immunotherapy; and has previously bought stock in the T-cell companies LionBiotech, Juno, Blue Bird, Kite Pharma, and ZioPharm. CC has received fees during the past 5 years for attending scientific meetings, speaking, organising research, and providing consulting services from AstraZeneca
Processing Request
No Comments.